ARRDC3 and breast carcinoma: ARRDC3 was demonstrated to inhibit PAR1-dependent Hippo signaling in breast cancer cells in a novel, PAR1-degradation-independent manner, by directly interacting with TAZ and inhibiting its activity [143].